natgillin/translations-raw huggingface dataset:
Akronymer og forkortelser AMR: Antimikrobiel resistens ARHAI: Program vedrżrende antimikrobiel resistens og infektioner erhvervet i sundhedsvžsenet CHAFEA: Forvaltningsorganet for Forbrugere, Sundhed, Landbrug og Fżdevarer EARS-Net: Det europžiske overvgningsnet for antimikrobiel resistens ECDC: Det Europžiske Center for Forebyggelse af og Kontrol med Sygdomme EFPIA: Den Europžiske Sammenslutning af Farmaceutindustriforeninger EFSA: Den Europžiske Fżdevaresikkerhedsautoritet EMA: Det Europžiske Lžgemiddelagentur EPHA: Den Europžiske Folkesundhedsalliance ESAC-Net: Det europžiske net til overvgning af forbruget af antimikrobielle stoffer ESVAC: Europžisk overvgning af veterinžrt forbrug af antimikrobielle stoffer Fžllesforetagendet for IMI: Fžllesforetagendet for initiativet om innovative lžgemidler GD RTD: Generaldirektoratet for Forskning og Innovation GD SANTE: Generaldirektoratet for Sundhed og Fżdevaresikkerhed HAI: Infektioner erhvervet i sundhedsvžsenet HAI-Net: Overvgningsnet for infektioner erhvervet i sundhedsvžsenet JAMRAI: Fžlles aktion om antimikrobiel resistens og infektioner erhvervet i sundhedsvžsenet JIACRA: Fžlles analyse af forbruget af antimikrobielle agenser og antibiotikaresistens JPIAMR: Fžlles programlžgningsinitiativ om antimikrobiel resistens NHP: National handlingsplan OECD: Organisationen for Żkonomisk Samarbejde og Udvikling 45 
Acronyms and abbreviations AMR: Antimicrobial Resistance ARHAI: Programme on Antimicrobial Resistance and Healthcare-Associated Infections CHAFEA: Consumers, Health, Agriculture and Food Executive Agency DG SANTE: Directorate-General for Health and Food Safety DG RTD: Directorate-General for Research and Innovation EARS-Net: European Antimicrobial Resistance Surveillance Network ECDC: European Centre for Disease Prevention and Control EFPIA: European Federation of Pharmaceutical Industries and Associations EFSA: European Food Safety Authority EMA: European Medicines Agency EPHA: European Public Health Alliance ESAC-Net: European Surveillance of Antimicrobial Consumption Network ESVAC: European Surveillance of Veterinary Antimicrobial Consumption HAI: Healthcare Associated Infections HAI-Net: Healthcare-Associated Infections Surveillance Network JIACRA: Joint Interagency Antimicrobial Consumption and Resistance Analysis JAMRAI: Joint Action on Antimicrobial Resistance and Healthcare-Associated Infections JPIAMR: Joint Programming Initiative on Antimicrobial Resistance JU IMI: Joint Undertaking Innovative Medicines Initiative NAP: National Action Plan OECD: Organization for Economic Co-operation and Development SME: Small and medium-sized enterprise TAFTAR: Transatlantic Taskforce on Antimicrobial Resistance WHO: World Health Organization 43
Antibiotikaresistens: Forekommer, nr bakterier udvikler resistens over for de antibiotika, som skulle držbe dem. 
Antibiotic resistance: Occurs when bacteria develops resistance to antibiotics that were designed to kill them.
Antibiotikum: Et antimikrobielt stof, der er aktivt mod bakterieinfektioner. 
Antimicrobial: An agent that kills or inhibits the growth of microbial organisms.
Antimikrobiel resistens: Evne hos mikroorganismer (f.eks. bakterier, vira, visse parasitter og fungi) til at modst antimikrobielle stoffer. 
Antimicrobial resistance: Is the ability of a microorganism (such as bacteria, viruses, some parasites and fungi) to stop an antimicrobial agent from working against it.
Mikroorganismer udvikler resistens ved genetisk mutation eller erhvervelse af genetisk information. 
Microorganisms develop resistance through genetic mutation or acquisition of the genetic information.
Et naturligt fžnomen, som forstžrkes ved misbrug og overforbrug af antimikrobielle lžgemidler. 
A natural phenomenon accelerated by the misuse and overuse of antimicrobial medicine.
Bredspektret antibiotikum: Et antibiotikum, som virker mod de to stżrste bakteriegrupper (de grampositive og de gramnegative) eller mod en bred vifte af sygdomsfremkaldende bakterier. 
Broad-spectrum antibiotic: An antibiotic that acts against the two major bacterial groups (gram-positive and gram-negative) or against a wide range of disease-causing bacteria.
Den europžiske One Health-handlingsplan mod antimikrobiel resistens: Kommissionens handlingsplan med henblik p at levere innovative, effektive og bžredygtige lżsninger p antimikrobiel resistens, styrke forskningen, fremme en global indsats og spille en fżrende rolle i bekžmpelsen af AMR. 
European One Health Action Plan against Antimicrobial Resistance: A Commission plan to deliver innovative, effective and sustainable responses to antimicrobial resistance; boost research, promote global action and play a leading role in the fight against AMR.
Gramnegative bakterier: En af de to stżrste bakteriegrupper. 
Gram-negative bacteria: One of the two major bacterial groups.
P grund af deres uigennemtržngelige cellevžg og medfżdte evne til at mutere og videregive genetisk materiale er disse bakterier i stigende grand resistente over for de fleste tilgžngelige antibiotika. 
Owing to their impenetrable cell wall and innate ability to mutate and pass on genetic material, these bacteria are increasingly resistant to most of the available antibiotics.
Infektioner erhvervet i sundhedsvžsenet: Infektioner, som mennesker fr under behandling p en sundhedsklinik, og som ikke var til stede eller under inkubation ved indlžggelsen. 
Healthcare associated infections: Infections people get in a medical facility while receiving treatment, which were not present or incubating at the time of their admission.
JAMRAI-arbejdspakker: Der er ni arbejdspakker: 1. koordinering; 2. spredning; 3. evaluering; 4. integrering i nationale politikker og bžredygtighed; 5. gennemfżrelse af nationale One Health-strategier og nationale handlingsplaner for AMR; 47 
Evaluation; 4. Integration in national policies and sustainability; 5. Implementation of one health national strategies and national actions plans for AMR; 6.
Metafylaktisk brug af veterinžre antibiotika: Behandling af en gruppe dyr, efter at en del af gruppen er diagnosticeret med infektion. 
Metaphylactic use of veterinary antibiotics: This refers to the treatment of a group of animals after the diagnosis of infection in part of the group.
National handlingsplan: En handlingsplan som udarbejdes og vedtages af en medlemsstat, og som er i overensstemmelse med mlene i den globale handlingsplan vedrżrende antimikrobiel resistens. 
National Action Plan: An action plan developed and adopted by Member State that is aligned with the objectives of the global action plan on antimicrobial resistance.
One Health: Et princip, som anerkender, at menneskers sundhed, dyrs sundhed og miljżet er forbundet. 
One Health: A principle, which recognises that the health of human, animal and environment are interconnected.
Superbug: En bakterie, der er resistent over for stżrstedelen af de almindeligt anvendte antibiotika i dag. 
Superbug: A bacterium that is resistant to the majority of antibiotics commonly used today.
WHO's globale handlingsplan vedrżrende antimikrobiel resistens: Den globale plan for bekžmpelse af antimikrobiel resistens, som blev vedtaget af Verdenssundhedsforsamlingen i 2015. Planen sigter mod at sikre en fortsat vellykket behandling og forebyggelse af smitsomme sygdomme med effektive og sikre lžgemidler. 
WHO Global Action Plan on Antimicrobial Resistance: The global plan to tackle antimicrobial resistance adopted by the World Health Assembly in 2015 that aims to ensure the ongoing successful treatment and prevention of infectious diseases with effective and safe medicines.
Zoonoser: Smitsomme sygdomme forrsaget af bakterier, vira eller parasitter, der spredes fra hvirveldyr til mennesker. 
Zoonosis (plural zoonoses): The infectious diseases caused by bacteria, viruses or parasites that spread from vertebrate animals to humans.
Store moderne sygdomme ssom ebolavirusinfektion og salmonellose er zoonoser. 
Major modern diseases such as Ebola virus disease and salmonellosis are zoonoses.
Zoonotiske og kommensale bakterier: Zoonotiske bakterier spreder sig fra hvirveldyr til mennesker, og kommensale bakterier lever i mennesker, normalt uden at forrsage skade. 48 
Zoonotic and commensal bacteria: Zoonotic bacteria spread from vertebrate animals to humans; and commensal bacteria live in human hosts typically without causing harm. 45
KOMMISSIONENS SVAR P DEN EUROPŽISKE REVISIONSRETS SŽRBERETNING "BEKŽMPELSE AF ANTIMIKROBIEL RESISTENS: DER ER FREMSKRIDT I DYRESEKTOREN, MEN DENNE SUNDHEDSTRUSSEL ER FORTSAT EN UDFORDRING FOR EU" RESUM III. 
REPLIES OF THE COMMISSION TO THE SPECIAL REPORT OF THE EUROPEAN COURT OF AUDITORS ŇADDRESSING ANTIMICROBIAL RESISTANCE: PROGRESS IN THE ANIMAL SECTOR, BUT THIS HEALTH THREAT REMAINS A CHALLENGE FOR THE EUÓ EXECUTIVE SUMMARY III.
Medlemsstaterne har hovedansvaret for tilrettelžggelse og levering af sundhedsydelser. 
Member States hold the main responsibility for the organisation and delivery of healthcare.
V Kommissionen pskżnner, at Revisionsretten giver omfattende oplysninger om de fremskridt, som Kommissionen har gjort med hensyn til bekžmpelse af AMR. 
V The Commission appreciates that the ECA provides ample information about the progress that is being made by the Commission in combatting AMR.
Dette omfatter rapporter fra medlemsstaterne om deres evaluering af Kommissionens aktiviteter til stżtte for deres indsats mod AMR. 
This includes the reports from Member States on their evaluation of Commission activities to support their actions on AMR.
Det fremgr af ECDC's skżn, at den sundhedsmžssige byrde ved AMR steg mellem 2007 og 2015. 
It is clear from estimates made by ECDC that the health burden of AMR rose between 2007 and 2015.
Det er imidlertid for tidligt at sige, om denne tendens er fortsat. 
However, it is too early to tell if this trend has continued.
Opdaterede skżn baseret p data fra perioden 2016-2019 ventes at vžre til rdighed fra ECDC i november 2020. 
Updated estimates, based on data from 2016-2019 are expected to be available from ECDC in November 2020.
VI Kommissionen og ECDC har ydet stżtte til One Health-tilgangen til AMR siden midten af 2017, hvor handlingsplanen blev vedtaget. 
VI The Commission and ECDC provide support to the One Health approach to AMR since mid-2017 as soon as the action plan was adopted.
Kommissionen og medlemsstaterne gennemgr lżbende resultatindikatorer for AMR, der offentliggżres af ECDC, EFSA og EMA. 
The Commission and Member States regularly review AMR outcome indicators, published by ECDC, EFSA and EMA.
Disse omfatter blandt andet niveauerne for resistente infektioner, AMR-dżdelighed og antibiotikaforbrug, som gennemgs af EU's Udvalg for Sundhedssikkerhed, og One Health-netvžrket for AMR. 
These include levels of resistant infection, AMR mortality and antibiotic consumption, reviewed in the EU Health Security Committee and the AMR One Health Network.
I veterinžrsektoren anvendes salget af antimikrobielle veterinžrlžgemidler som en indikator under projektet europžisk overvgning af veterinžrt forbrug af antimikrobielle stoffer (ESVAC). 
In the veterinary sector, sales of veterinary antimicrobial agents are used as an indicator under the European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) project.
Den nye forordning (EU) 2019/6 om veterinžrlžgemidler vil styrke dette initiativ ved at fastsžtte en retlig forpligtelse for medlemsstaterne til ikke kun at indsamle data om salg, men ogs data om forbrug pr. art af antimikrobielle stoffer til dyr. 
The new Regulation (EU) 2019/6 on veterinary medicinal products will strengthen this initiative, by providing for the legal obligation for Member States not only to collect data on sales, but also data on use per species of antimicrobials in animals.
Dette bżr give medlemsstaterne og Kommissionen mulighed for at mlrette deres indsats mod AMR yderligere. 
This should allow the Member States and the Commission to further target their action against AMR.
AMR-handlingsplanen anerkender fuldt ud den manglende viden om forekomsten og spredningen af AMR i miljżet og indeholder specifikke foranstaltninger til at lukke disse huller. 
The AMR action plan fully recognizes the knowledge gap on the occurrence and spread of AMR in the environment and contains specific actions to close these gaps.
Kommissionen har for nylig vedtaget en meddelelse om EU's strategi for lžgemidler i miljżet, som viser Kommissionens engagement p dette omrde. 
Recently, the Commission adopted a communication on the EU strategic approach to pharmaceuticals in the environment which shows the Commission commitment in this area.
VIII Med hensyn til markedet for antimikrobielle stoffer er der mange incitamenter p plads, og den eksisterende lžgemiddellovgivning giver en ržkke incitamenter til innovative lžgemidler. 
VIII With regard to the antimicrobials market, there are many push incentives in place and the existing pharmaceutical legislation provides some pull incentives for innovative medicinal products.
Der skal tages hensyn til den nuvžrende situation i debatten om nye incitamenter eller andre mekanismer til afhjžlpning af markedssvigt med hensyn til udvikling og tilgžngelighed af antimikrobielle stoffer. 
The existing landscape has to be taken into account in the discussion about novel incentives or other mechanisms to address market failures with regard to the development and availability of antimicrobials.
Den nye forordning (EU) 2019/6 om veterinžrlžgemidler indeholder bestemmelser om en forenklet vurderingsprocedure og en databeskyttelsesperiode, som p visse betingelser kan forlžnges op til 18 r. 
The new Regulation (EU) 2019/6 on veterinary medicinal products provides for a simplified assessment procedure and a data protection period, which may be extended up to 18 years under certain conditions.
Sdanne bestemmelser har navnlig til forml at stimulere udviklingen og żge tilgžngeligheden af veterinžrlžgemidler ssom antimikrobielle lžgemidler. 
Such provisions intend notably to stimulate the development and enhance the availability of veterinary medicinal products, such as antimicrobial medicinal products.
Kommissionen har fastlagt sin overordnede forskningsstrategi i sin europžiske One Health-handlingsplan mod AMR, og den har finansieret JPIAMR's strategiske forsknings-og innovationsdagsorden. INDLEDNING DA DA 1 
The Commission has set out its overarching research strategy in its European One Health Action Plan against AMR, and it has funded the JPIAMR Strategic Research and Innovation Agenda.
12 Medlemsstaterne har hovedansvaret for tilrettelžggelse og levering af sundhedsydelser. 
INTRODUCTION 12 Member States hold the main responsibility for the organisation and delivery of healthcare.
13 Med afgżrelse 1082/2013/EU etableres systemet for tidlig varsling og reaktion (EWRS), og der fastlžgges specifikke kriterier for varslingsrapporteringer vedrżrende alvorlige gržnseoverskridende sundhedstrusler. 
13 Decision (EU) 1082/2013 establishes the Early Warning and Response System (EWRS) and sets out specific criteria for alert notifications of serious cross-border health threats.
De nationale kompetente myndigheder skal kun rapportere varslinger, nr en trussel opfylder specifikke kriterier. 
National competent authorities must notify alerts only when a threat fulfils specific criteria.
Derfor vil ikke alle tilfžlde af AMR og infektioner erhvervet i sundhedsvžsenet, som falder ind under den epidemiologiske overvgning, blive rapporteret af EWRS. 
Thus, not all cases of AMR and healthcare associated infections that fall under epidemiological surveillance would be reported by the EWRS.
Boks 1 - EU-agenturernes rolle i AMR Derudover stżtter EMA udviklere, navnlig SMV'er og den akademiske verden, og fremmer udviklingen af antibiotika gennem dedikerede ordninger for innovative lžgemidler ssom den innovative taskforces aktiviteter eller PRIME1. BEMŽRKNINGER 36 EU's One Health-handlingsplan mod antimikrobiel resistens anerkender fuldt ud den manglende viden om forekomsten og spredningen af AMR i miljżet og indeholder specifikke foranstaltninger til at lukke disse huller. 
Box 1 - The role of EU agencies in AMR Additionally, EMA supports developers, in particular SMEs and academia and facilitates the development of antibiotics through dedicated schemes for innovative medicines such as the Innovative Task Force activities or the PRIME.1 OBSERVATIONS 36 The EU one Health action plan against AMR fully recognizes the knowledge gap on the occurrence and spread of AMR in the environment and contains specific actions to close these gaps.
48 For s vidt angr markedet for antimikrobielle stoffer er der mange incitamenter p plads, og den eksisterende lžgemiddellovgivning giver en ržkke incitamenter til innovative lžgemidler. 
48 With regard to the antimicrobials market, there are many push incentives in place and the existing pharmaceutical legislation provides some pull incentives for innovative medicinal products.
49 Kommissionen har evalueret sin żkonomiske investering i forskning og innovation p AMR-omrdet ved hjžlp af den kortlžgning, der foretages af JPIAMR (som blev finansieret via et EU-tilskud). 
49 The Commission has evaluated its financial investment in AMR research and innovation, through the mapping performed by JPIAMR (which was financed via an EU grant).
Den fulde virkning af denne investering er imidlertid ikke blevet grundigt evalueret. 
However, the full impact of this investment has not been comprehensively evaluated.
55 Kommissionen har afsat midler til etablering af det nye netvžrk for kliniske forsżg i 2021. 
55 The Commission has earmarked funding for the establishment of the new clinical trials network in 2021.
57 Kommissionen har fastlagt sin overordnede forskningsstrategi i sin europžiske One Health-handlingsplan mod antimikrobiel resistens, og den har finansieret JPIAMR's strategiske forsknings-og innovationsdagsorden. 
57 The Commission has set out its overarching research strategy in its European One Health Action Plan against AMR, and it has funded the JPIAMR Strategic Research and Innovation Agenda.
Kommissionen erkender dog, at nogle af de store udfordringer, der er forbundet med AMR-forskning, ikke behandles tilstržkkeligt i strategien. 
However, the Commission acknowledges that some of the important challenges facing AMR research are not sufficiently addressed in the strategy.
KONKLUSIONER OG ANBEFALINGER 66 Kommissionen og ECDC har ydet stżtte til One Health-tilgangen til AMR siden midten af 2017, hvor handlingsplanen blev vedtaget. 
CONCLUSIONS AND RECOMMENDATIONS 66 The Commission and ECDC provide support to the One Health approach to AMR since mid-2017 when the action plan was adopted.
Da det generelt varer omkring to r, fżr statistikkerne for resultaterne foreligger, er det for tidligt at vurdere virkningerne eller resultaterne med hensyn til reduktion af sundhedsbyrden. 
As statistics on outcomes generally take around two years to become available, it is too early to assess impacts or results in terms of reduction in health burden.
68 Kommissionen og medlemsstaterne gennemgr lżbende de resultatindikatorer for AMR, der er offentliggjort af ECDC, EFSA og EMA. 
68 The Commission and Member States regularly review the AMR outcome indicators which are published by the ECDC, EFSA and EMA.
Disse omfatter blandt andet niveauerne for resistente infektioner, AMR-dżdelighed og antibiotikaforbrug, som gennemgs i EU's Udvalg for Sundhedssikkerhed og i andre fora Đ herunder det rumžnske formandskabs konference om AMR i 2019 og One Health-netvžrket for AMR. 
These include levels of resistant infection, AMR mortality and antibiotic consumption which are reviewed in the EU Health Security Committee and in other forums Đ including the 2019 Romania Presidency Conference on AMR and the AMR One Health Network.
1 https://www.ema.europa.eu/en/human-regulatory/research-development/innovation-medicines https://www.ema.europa.eu/en/human-regulatory/research-development/prime-priority-medicines DA DA 2 
1 https://www.ema.europa.eu/en/human-regulatory/research-development/innovation-medicines https://www.ema.europa.eu/en/human-regulatory/research-development/prime-priority-medicines EN EN 2
DA DA Medlemsstaterne er forpligtet til at indberette overvgningsdata om infektioner erhvervet i sundhedsvžsenet til EU-niveau. 
Reporting surveillance data on HAIs to the EU level is an obligation of Member States.
ECDC overvger og stiller vžrktżjer til rdighed for at forbedre denne indberetning ved at koordinere punktpržvalensundersżgelser af infektioner erhvervet i sundhedsvžsenet og stille "light" (minimum) tilsynsprotokoller til rdighed for at tilskynde alle medlemsstater til at foretage indberetning. 
ECDC monitors and provides tools for improving such reporting by coordinating point prevalence surveys of HAIs and providing ÔlightŐ (minimum) surveillance protocols to encourage reporting by all Member States.
Den europžiske One Health-handlingsplan mod antimikrobiel resistens anerkender fuldt ud den manglende viden om forekomsten og spredningen af AMR i miljżet og indeholder specifikke foranstaltninger til at lukke disse huller. 
The European One Health Action Plan against AMR fully recognizes the knowledge gap on the occurrence and spread of AMR in the environment and contains specific actions to close these gaps.
Kommissionen har for nylig vedtaget en meddelelse om EU's strategi for lžgemidler i miljżet2, som viser Kommissionens engagement p dette omrde. 
Recently, the Commission adopted a communication on the EU strategic approach to pharmaceuticals in the environment2 which shows the Commission commitment in this area.
Anbefaling 1 Đ Forbedring af EU's reaktion p AMR gennem bedre stżtte til medlemsstaternes nationale handlingsplaner Kommissionen accepterer anbefaling 1a. Kommissionen accepterer anbefaling 1b. 
Recommendation 1 Đ Improving the EU response to AMR through better support to Member State national action plans The Commission accepts recommendation 1a The Commission accepts recommendation 1b.
Kommissionen accepterer anbefaling 1c. Anbefaling 2 Đ Fremme af bedre overvgning og hensigtsmžssig anvendelse af antimikrobielle veterinžrlžgemidler Kommissionen accepterer anbefaling 2. 71 Med hensyn til markedet for antimikrobielle stoffer, er der mange incitamenter p plads, og den eksisterende lžgemiddellovgivning giver en ržkke incitamenter til innovative lžgemidler. 
The Commission accepts recommendation 1c Recommendation 2 Đ Promoting better monitoring and the antimicrobials The Commission accepts recommendation 2. prudent use of veterinary 71 With regard to the antimicrobials market, there are many push incentives in place and the existing pharmaceutical legislation provides some pull incentives for innovative medicinal products.
Der skal tages hensyn til den nuvžrende situation i debatten om nye incitamenter eller andre mekanismer til afhjžlpning af markedssvigt med hensyn til udvikling af antimikrobielle stoffer. 
The existing landscape has to be taken into account in the discussion about novel incentives or other mechanisms to address market failures with regard to the development of antimicrobials.
72 Kommissionen har fastlagt sin overordnede forskningsstrategi i sin europžiske One Health-handlingsplan mod antimikrobiel resistens, og den har finansieret JPIAMR's strategiske forsknings-og innovationsdagsorden. 
72 The Commission has set out its overarching research strategy in its European One Health Action Plan against AMR, and it has funded the JPIAMR Strategic Research and Innovation Agenda.
73 Nogle antibiotika, der stadig har effekt, tržkkes tilbage fra markedet. 
73 Some antibiotics that continue to work are withdrawn from the market.
Dette er en ensidig beslutning fra medicinalfirmaerne. Kommissionen har begržnsede muligheder for at pvirke dem trods sine bestržbelser p at vžre mere proaktiv. 
This is a unilateral decision of the pharmaceutical companies where the Commission has limited possibilities to influence them despite efforts to be more proactive.